Repare Therapeutics Inc. (NASDAQ:RPTX) Major Shareholder Bvf Partners L. P/Il Buys 6,869 Shares

Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) major shareholder Bvf Partners L. P/Il acquired 6,869 shares of the stock in a transaction on Monday, June 6th. The stock was acquired at an average cost of $13.21 per share, for a total transaction of $90,739.49. Following the acquisition, the insider now directly owns 4,368,757 shares in the company, valued at approximately $57,711,279.97. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

NASDAQ RPTX traded up $0.97 during trading hours on Monday, reaching $14.10. The company’s stock had a trading volume of 994,472 shares, compared to its average volume of 551,566. The company’s 50-day moving average is $11.10 and its two-hundred day moving average is $15.17. Repare Therapeutics Inc. has a fifty-two week low of $8.06 and a fifty-two week high of $35.75. The stock has a market cap of $590.71 million, a PE ratio of -4.28 and a beta of 0.92.

Repare Therapeutics (NASDAQ:RPTX – Get Rating) last released its quarterly earnings results on Thursday, May 5th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.86) by $0.03. Repare Therapeutics had a negative net margin of 1,533.38% and a negative return on equity of 47.60%. As a group, equities research analysts forecast that Repare Therapeutics Inc. will post -3.37 earnings per share for the current year.

Several research firms have recently commented on RPTX. Stifel Nicolaus cut Repare Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, April 12th. HC Wainwright decreased their target price on shares of Repare Therapeutics from $54.00 to $38.00 and set a “buy” rating on the stock in a research report on Monday. Zacks Investment Research raised shares of Repare Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, May 12th. The Goldman Sachs Group assumed coverage on shares of Repare Therapeutics in a report on Thursday, March 17th. They set a “buy” rating and a $43.00 price objective on the stock. Finally, Piper Sandler increased their target price on shares of Repare Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, Repare Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $43.13.

A number of large investors have recently made changes to their positions in RPTX. National Bank of Canada FI purchased a new position in Repare Therapeutics during the fourth quarter worth $43,000. Legal & General Group Plc increased its position in Repare Therapeutics by 55.5% during the 4th quarter. Legal & General Group Plc now owns 3,923 shares of the company’s stock worth $83,000 after purchasing an additional 1,400 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. increased its position in Repare Therapeutics by 9.5% during the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 11,580 shares of the company’s stock worth $165,000 after purchasing an additional 1,002 shares in the last quarter. Virtus ETF Advisers LLC raised its stake in Repare Therapeutics by 28.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 8,355 shares of the company’s stock valued at $176,000 after purchasing an additional 1,873 shares during the last quarter. Finally, California State Teachers Retirement System purchased a new position in Repare Therapeutics in the 3rd quarter valued at about $198,000. Hedge funds and other institutional investors own 89.66% of the company’s stock.

About Repare Therapeutics (Get Rating)

Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.

See Also